The GUF1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the GUF1 gene in the HAP1 near-haploid human cell line. This polyclonal population, generated via CRISPR/Cas9-mediated gene disruption, provides a robust loss-of-function model for studying the mitochondrial ribosome recycling factor GUF1. Unlike monoclonal lines, the polyclonal format captures a spectrum of edited alleles, enabling broad functional interrogation while maintaining the genetic simplicity of the host system. Researchers can utilize these cells to dissect the role of GUF1 in mitochondrial translation without the confounding effects of a diploid genome, making it a versatile tool for both mechanistic studies and drug discovery applications.
HAP1 cells are a near-haploid human chronic myeloid leukemia (CML) cell line derived from the KBM-7 parental line. Their near-haploid karyotype??containing a single copy of most chromosomes except for a disomic region??renders them exceptionally tractable for reverse genetic approaches such as CRISPR/Cas9 knockout. This feature simplifies the generation of complete gene disruptions, as only one allele must be targeted, leading to a functionally null phenotype in the majority of cases. HAP1 cells retain key cancer-relevant signaling pathways and metabolic characteristics of the CML lineage, providing a physiologically relevant human background for investigating mitochondrial biology and its intersection with oncogenic processes.
GUF1 encodes a mitochondrial ribosome recycling factor that catalyzes the GTP-dependent release of mRNA and deacylated tRNA from post-termination ribosomal complexes, thereby preparing the mitochondrial ribosome for new rounds of translation. This protein functions downstream of mitochondrial import machinery and is dynamically regulated by GTP availability. GUF1 directly interacts with the mitochondrial ribosome, mtRRF (the mitochondrial ribosome recycling factor homolog), and GTP to drive subunit dissociation. Its activity modulates mitochondrial translation efficiency and mitochondrial protein synthesis, placing it at a critical node in the mitochondrial translation pathway. Impairment of GUF1 is linked to mitochondrial translation deficiency and emerging evidence suggests a role in neurodevelopmental disorders, underscoring its biological and clinical significance.
Within the HAP1 cellular context, knockout of GUF1 perturbs mitochondrial protein synthesis, leading to deficits in oxidative phosphorylation and altered cellular metabolism. The near-haploid background amplifies these effects, enabling clear observation of phenotypes such as reduced oxygen consumption rates, compromised cell viability under metabolic stress conditions like galactose-dependent growth, and accumulation of mitochondrial translation intermediates. This model system therefore facilitates the study of mitochondrial ribosome recycling in a cancer cell lineage, offering insights into how mitochondrial dysfunction influences tumor cell fitness and sensitivity to metabolic stress. Moreover, the HAP1 platform allows for combinatorial genetic or pharmacological manipulations to explore synthetic lethal interactions and bypass mechanisms.
Typical applications of the GUF1 Knockout HAP1 Polyclonal Cells include the elucidation of mitochondrial translation mechanisms through assays such as Western blotting of mitochondrial-encoded proteins, RT-qPCR analysis of mitochondrial transcripts, and metabolic labeling of nascent mitochondrial peptides. Functional assessments can involve oxygen consumption rate measurements using Seahorse analyzers or cell viability assays under conditions that force oxidative phosphorylation reliance. The model is well-suited for studying mitochondrial translation deficiency, modeling neurodevelopmental aspects of GUF1 dysfunction, and testing small-molecule modulators or rescue strategies. Additionally, it can be employed in genetic interaction screens to identify compensatory pathways. For further technical details or ordering information, please contact Ascent Research.
